{"id":5104,"date":"2021-12-11T09:59:00","date_gmt":"2021-12-11T09:59:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=5104"},"modified":"2025-01-14T21:36:23","modified_gmt":"2025-01-14T21:36:23","slug":"progress-towards-achieving-viral-hepatitis-b-and-c-elimination-in-the-asia-and-pacific-region-results-from-modelling-and-global-reporting","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/progress-towards-achieving-viral-hepatitis-b-and-c-elimination-in-the-asia-and-pacific-region-results-from-modelling-and-global-reporting\/","title":{"rendered":"Progresos hacia la eliminaci\u00f3n de las hepatitis virales B y C en la regi\u00f3n de Asia y el Pac\u00edfico: resultados de la elaboraci\u00f3n de modelos y la presentaci\u00f3n de informes a nivel mundial"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<p>En 2016, los pa\u00edses de Asia y el Pac\u00edfico aprobaron planes de acci\u00f3n para alcanzar los objetivos de eliminaci\u00f3n de la hepatitis viral establecidos en la Estrategia mundial del sector de la salud (GHSS) para la hepatitis viral 2016-2021. Examinamos el progreso de la regi\u00f3n modelando la carga de enfermedad y construyendo la cascada de atenci\u00f3n. Entre 2015 y 2020, la prevalencia cr\u00f3nica del VHB disminuy\u00f3 de 4,691 TP2T a 4,301 TP2T, y la prevalencia del VHC disminuy\u00f3 de 0,641 TP2T a 0,581 TP2T. La regi\u00f3n alcanz\u00f3 el objetivo de 2020 de reducci\u00f3n de la incidencia de 30% para el VHB, mientras que la incidencia del VHC disminuy\u00f3 en 6%. La incidencia de carcinoma hepatocelular para HBV y HCV aument\u00f3 en 9% y 7%, respectivamente. Las muertes por VHB relacionadas con el h\u00edgado aumentaron en 8% y la mortalidad atribuible al VHC se estabiliz\u00f3. En 2019 quedaron grandes brechas en las pruebas y el tratamiento: solo se diagnosticaron 13% de infecciones cr\u00f3nicas por VHB y se trataron 25%; Se diagnosticaron 21% de infecci\u00f3n cr\u00f3nica por VHC y se trat\u00f3 11%. La hepatitis viral debe convertirse en una prioridad nacional con la financiaci\u00f3n adecuada para alcanzar los objetivos de eliminaci\u00f3n para 2030.<\/p>\n\n\n\n<p><strong>Pa\u00edses\/Territorios:<\/strong> Asia y el Pac\u00edfico<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34894047\/\" style=\"border-radius:6px;color:#951b23\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary In 2016, Asia and Pacific countries endorsed action plans for reaching viral hepatitis elimination targets set in the Global Health Sector Strategy (GHSS) for Viral Hepatitis 2016-2021. We examine the region&#8217;s progress by modelling disease burden and constructing the cascade of care. Between 2015 and 2020, chronic HBV prevalence declined from 4.69% to 4.30%, [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3486,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[31,21,10,12],"publication-author":[488,490,491,489,487,496,495,494,497,492,493],"class_list":["post-5104","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-elimination","tag-hbv","tag-hcv","tag-modelling","publication-author-blach-s","publication-author-chan-p","publication-author-fuqiang-c","publication-author-ishikawa-n","publication-author-le-lv","publication-author-low-beer-d","publication-author-mangadan-konath-n","publication-author-razavi-h","publication-author-razavi-shearer-d","publication-author-rewari-b","publication-author-sharma-m"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/5104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=5104"}],"version-history":[{"count":2,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/5104\/revisions"}],"predecessor-version":[{"id":7437,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/5104\/revisions\/7437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3486"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=5104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=5104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=5104"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=5104"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}